PharmaNutra S.p.A. has taken a significant step in its North American growth strategy by signing a distribution agreement with Sigma Lifesciences, a Canadian pharmaceutical company specializing in health product production and distribution. This collaboration marks PharmaNutra’s entry into the Canadian market, where Sigma Lifesciences will manage the distribution of its SiderAL® line of supplements and Ultramag®, all based on PharmaNutra’s innovative Sucrosomial® Technology.
The agreement includes SiderAL® Forte, SiderAL® Folic, and SiderAL® Drops, known for their enhanced absorption and tolerability in delivering iron, as well as Ultramag®, a magnesium supplement. Health Canada has officially approved all four products for commercialization.
To gear up for the Q2 2025 launch, PharmaNutra conducted a training session in Toronto, engaging over 30 Canadian healthcare professionals across various specialties to familiarize them with the technology and tailor strategies for local market needs. This deal further solidifies PharmaNutra’s presence in over 80 countries globally.
